Silent suppression for Antisense
Wednesday, 15 October, 2008
Preclinical trials of Antisense Therapeutics’ [ASX: ANP] ATL1101 candidate have been shown to suppress human prostate tumour growth in animal models.
ATL1101 suppressed the growth of human tumours in mice that had been implanted with human prostate cancer sells.
The treatment slowed down the cancerous cells' transition to the most dangerous form of prostate cancer, castration-resistant prostate cancer [CRPC].
The study was conducted with the assistance of Martin Gleave, the director of the Prostate Centre at Vancouver General Hospital.
This is the first known demonstration of the efficacy of RNA-silencing IGF-I receptor drugs in prostate cancer models.
Shorter radiotherapy course proves safe for prostate cancer
A significantly shorter course of radiotherapy for localised prostate cancer is just as safe and...
5-in-1 meningococcal vaccine proves effective
A life-saving meningococcal vaccine covering all five common strains of the deadly disease could...
Diabetes drug reduces knee arthritis pain in overweight patients
A common diabetes drug can reduce the pain of people with knee osteoarthritis and overweight or...
